[go: up one dir, main page]

ATE331718T1 - Spirosubstituierte pyrrolopyrimidine - Google Patents

Spirosubstituierte pyrrolopyrimidine

Info

Publication number
ATE331718T1
ATE331718T1 AT04715273T AT04715273T ATE331718T1 AT E331718 T1 ATE331718 T1 AT E331718T1 AT 04715273 T AT04715273 T AT 04715273T AT 04715273 T AT04715273 T AT 04715273T AT E331718 T1 ATE331718 T1 AT E331718T1
Authority
AT
Austria
Prior art keywords
cathepsin
spiro
formula
substituted pyrrolopyrimidines
compounds
Prior art date
Application number
AT04715273T
Other languages
English (en)
Inventor
Osamu Irie
Genji Iwasaki
Keiichi Masuya
Takahiro Miyake
Naoki Teno
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE331718T1 publication Critical patent/ATE331718T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04715273T 2003-02-28 2004-02-27 Spirosubstituierte pyrrolopyrimidine ATE331718T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0304640.6A GB0304640D0 (en) 2003-02-28 2003-02-28 Organic compounds

Publications (1)

Publication Number Publication Date
ATE331718T1 true ATE331718T1 (de) 2006-07-15

Family

ID=9953876

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715273T ATE331718T1 (de) 2003-02-28 2004-02-27 Spirosubstituierte pyrrolopyrimidine

Country Status (18)

Country Link
US (2) US7531546B2 (de)
EP (1) EP1601677B1 (de)
JP (1) JP2006519207A (de)
CN (1) CN100341876C (de)
AT (1) ATE331718T1 (de)
AU (1) AU2004215648B2 (de)
BR (1) BRPI0407919A (de)
CA (1) CA2517035A1 (de)
CY (1) CY1105637T1 (de)
DE (1) DE602004001397T2 (de)
DK (1) DK1601677T3 (de)
ES (1) ES2268633T3 (de)
GB (1) GB0304640D0 (de)
HK (1) HK1089156A1 (de)
MX (1) MXPA05009157A (de)
PL (1) PL378469A1 (de)
PT (1) PT1601677E (de)
WO (1) WO2004076455A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
WO2007028638A1 (en) 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
CA2630492C (en) * 2005-12-05 2015-04-14 Incyte Corporation Spiro-lactam compounds
US20080200454A1 (en) * 2007-02-15 2008-08-21 Ameriks Michael K Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090118274A1 (en) * 2007-02-15 2009-05-07 Darin Allen Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080207683A1 (en) * 2007-02-15 2008-08-28 Darin Allen Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20080269241A1 (en) * 2007-02-15 2008-10-30 Darin Allen Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s
US20090099157A1 (en) * 2007-02-15 2009-04-16 Ameriks Michael K Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s
CN101678011B (zh) * 2007-05-16 2012-07-18 默沙东公司 螺氮茚酮化合物
EP2268647B1 (de) 2008-03-21 2017-01-25 The General Hospital Corporation Verbindungen und zusammensetzungen für den nachweis und die behandlung von morbus alzheimer und verwandten erkrankungen
AR077280A1 (es) 2009-06-29 2011-08-17 Incyte Corp Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2558463A1 (de) 2010-04-14 2013-02-20 Incyte Corporation Kondensierte derivate als i3-hemmer
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2655374B1 (de) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituierte phenyl)ethyl)-9h-purin-6-amine als pi3k-hemmer
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
SMT202100288T1 (it) 2011-09-02 2021-07-12 Incyte Holdings Corp Eterociclilammine come inibitori di pi3k
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
US9328118B2 (en) * 2012-04-17 2016-05-03 Astellas Pharma Inc. Nitrogen-containing bicyclic aromatic heterocyclic compound
WO2014060411A1 (en) * 2012-10-16 2014-04-24 Janssen R&D Ireland Rsv antiviral compounds
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
KR20240132104A (ko) 2015-02-27 2024-09-02 인사이트 홀딩스 코포레이션 Pi3k 억제제의 염 및 이의 제조 공정
WO2016179157A1 (en) 2015-05-05 2016-11-10 Carafe Drug Innovation, Llc Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107935908A (zh) * 2016-10-12 2018-04-20 上海科胜药物研发有限公司 一种尼达尼布（nintedanib）的制备方法及其中间体
US11299478B2 (en) 2018-03-28 2022-04-12 Hanlim Pharmaceutical Co., Ltd. 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same
SG11202011680YA (en) 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
US20240174695A1 (en) * 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225036A1 (en) 2000-03-20 2003-12-04 Aleksandr Kolesnikov Non-amidine containing protease inhibitors
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
PE20050068A1 (es) * 2003-02-06 2005-03-11 Novartis Ag 2-cianopirrolopirimidinas como inhibidores de la catepsina s

Also Published As

Publication number Publication date
BRPI0407919A (pt) 2006-03-01
JP2006519207A (ja) 2006-08-24
US7531546B2 (en) 2009-05-12
GB0304640D0 (en) 2003-04-02
HK1089156A1 (en) 2006-11-24
MXPA05009157A (es) 2005-10-20
AU2004215648A1 (en) 2004-09-10
CA2517035A1 (en) 2004-09-10
PT1601677E (pt) 2006-11-30
ES2268633T3 (es) 2007-03-16
WO2004076455A1 (en) 2004-09-10
DE602004001397T2 (de) 2007-04-26
PL378469A1 (pl) 2006-04-03
EP1601677B1 (de) 2006-06-28
US20090186889A1 (en) 2009-07-23
CN100341876C (zh) 2007-10-10
DK1601677T3 (da) 2006-10-30
CY1105637T1 (el) 2010-12-22
CN1753895A (zh) 2006-03-29
EP1601677A1 (de) 2005-12-07
DE602004001397D1 (de) 2006-08-10
US20060258690A1 (en) 2006-11-16
AU2004215648B2 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
ATE331718T1 (de) Spirosubstituierte pyrrolopyrimidine
GB0220187D0 (en) Organic compounds
GB0121033D0 (en) Organic compounds
MXPA04001930A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflaciones y otras enfermedades.
NO20044038L (no) Glutaminylbaserte DRIV-inhibitorer
NO20030895D0 (no) Ny anvendelse av dipeptidyl peptidase IV inhibitorer
EP2295433A3 (de) JNK Inhibitoren
GB0223040D0 (en) Therapeutic compounds
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
MX2010009658A (es) Derivados de azetidina.
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
MY128242A (en) Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1 and tnf
ECSP044989A (es) Inhibidores de proteasa de cisteina con estructura de 2-ciano-4-amino-pirimidina y actividad inhibidora de catepsina k para el tratamiento de inflamaciones y otras enfermedades
MXPA05006296A (es) Uso de tiazolobenzoheterociclos para el tratamiento de la esclerosis multiple.
DOP2003000728A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenetivos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1601677

Country of ref document: EP

REN Ceased due to non-payment of the annual fee